Evidence map›Paper›PMID 31192220›Full record

ReviewMolecular neuropsychiatry2019

Electroconvulsive Therapy and Schizophrenia: A Systematic Review.

Sana A Ali, Nandita Mathur, Anil K Malhotra, Raphael J Braga

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Molecular neuropsychiatry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Phosphatase Signaling as a Therapeutic Strategy in Schizophrenia.International journal of molecular sciences · 2026
    Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Observational
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Sana A AliDivision of Psychiatry Research, The Zucker Hillside Hospital, Northwell Health, New York, New York, USA.
Nandita MathurDivision of Psychiatry Research, The Zucker Hillside Hospital, Northwell Health, New York, New York, USA.
Anil K MalhotraDivision of Psychiatry Research, The Zucker Hillside Hospital, Northwell Health, New York, New York, USA.
Raphael J BragaDivision of Psychiatry Research, The Zucker Hillside Hospital, Northwell Health, New York, New York, USA.

Funding

Striatal D2/D3 Dopamine receptor availability in first episode schizophreniaP50MH080173 · NIMH · FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH · PI SMITH, GWENN S · 2008 to 2012
$10.4M
Connectivity Biomarkers of Clinical Response in Treatment Resistant SchizophreniaR01MH109508 · NIMH · FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH · PI MALHOTRA, ANIL K · 2017 to 2021
$3.4M
NIMH NIH HHS P50 MH080173NIMH NIH HHS R01 MH109508
6 · The paper itself

Abstract

Electroconvulsive therapy (ECT) is a remarkably effective treatment for major depressive disorder, but is less commonly utilized for treatment of psychotic disorders. Recent literature indicates that ECT can be a useful strategy for a wide range of psychotic disorders, including treatment-resistant schizophrenia. The purpose of this review is to examine the extant literature on ECT in schizophrenia with a primary focus on its efficacy, its impact on cognitive function, the role of maintenance ECT, and the potential role of neuroimaging biomarkers to provide more precise ECT treatment strategies. We evaluated the available literature, with a particular focus on prospective, randomized trials. Our review suggests that ECT can be an effective treatment strategy in this severely ill patient population. Studies suggest that while ECT in schizophrenia is a safe treatment modality, the potential for cognitive impairment must always be carefully weighed. The use and investigation of new biomarker strategies for the pharmacological treatment of schizophrenia, and the extension of these approaches to ECT are also discussed.

Indexed as

BiomarkersElectroconvulsive therapySchizophreniaTreatment

Identifiers

PMID31192220
PMCPMC6528094

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.